Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963570 | 0.62 | POLB (0.37) | KDM5AKDM4CKDM5B | |
| SCHEMBL30963447 | 0.62 | ALDH1A1 (0.39) | KDM5AKDM4CKDM5B | |
| SCHEMBL23130273 | 0.61 | CYP2C9 (0.49) | KDM5AKDM4CKDM5B | |
| SCHEMBL30963530 | 0.59 | KDM5A (0.34) | KDM5AKDM4CKDM5B | |
| SCHEMBL19851900 | 0.59 | — | — | |
| SCHEMBL15779574 | 0.59 | OXTR (0.48) | KDM5AKDM4CKDM5B | |
| SCHEMBL19453172 | 0.59 | OXTR (0.48) | — | |
| SCHEMBL15299343 | 0.59 | NPC1 (0.41) | KDM5AKDM4CKDM5B | |
| SCHEMBL18725081 | 0.59 | KDM5A (0.37) | KDM5AKDM4CKDM5B | |
| SCHEMBL30963554 | 0.59 | POLB (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | KDM5A 3655/4885KDM4C 3495/4885KDM5B 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.